名稱 | ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat |
型號 | CBP74105 |
報價 | |
特點 | ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat,母細胞:Jurkat,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
聯(lián)系人:蔣經(jīng)理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
- 詳細內(nèi)容
CBP74105 | |
I. Background | |
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. | |
II. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | FcγRIa_NFAT |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | N/A |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin |
Storage: | Liquid nitrogen. |
Application(s): | Functional(Report Gene) Assay |
III. Description of Host Cell Line | |
Organism: | Human |
Tissue: | Peripheral blood |
Disease: | Childhood T acute lymphoblastic leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
IV.Representative Data | |
Figure 1:Dose response of Rituximab in ADCP Bioassay Effector Cell FcγRIa/NFAT Reporter-Jurkat (C11),the EC50 was 1.94ng/ml. |